Moxisylyte
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | G04BE06 (WHO) C04AX10 (WHO) |
| Identifiers | |
| |
| CAS Number |
54-32-0 |
| PubChem (CID) | 4260 |
| ChemSpider | 4110 |
| UNII |
PW8QYA7KI0 |
| KEGG |
D08239 |
| ECHA InfoCard | 100.000.186 |
| Chemical and physical data | |
| Formula | C16H25NO3 |
| Molar mass | 279.375 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction.[1] It is an α1-adrenergic antagonist.[2]
References
- ↑ British National Formulary 69, Chapter2.6.4, page 142
- ↑ Sakakibara R, Hattori T, Uchiyama T, et al. (March 2000). "Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte". J. Auton. Nerv. Syst. 79 (2–3): 191–5. doi:10.1016/S0165-1838(99)00105-8. PMID 10699651.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
